scPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection
Portfolio Pulse from Benzinga Newsdesk
scPharmaceuticals has started enrolling participants for a pivotal pharmacokinetic study of its FUROSCIX Auto-Injector, aimed at complementing the existing FUROSCIX On-body Infusor. The company expects to release topline data by Q3 2024 and plans to submit a Supplemental New Drug Application (sNDA) by the end of 2024, contingent on positive results.
April 24, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
scPharmaceuticals begins pivotal study for FUROSCIX Auto-Injector, with topline data expected in Q3 2024 and a possible sNDA submission by end of 2024.
The initiation of a pivotal pharmacokinetic study for the FUROSCIX Auto-Injector by scPharmaceuticals is a significant development step, indicating progress towards regulatory approval and commercialization. Positive study results and a subsequent sNDA submission could significantly impact the company's valuation and investor sentiment, likely leading to a positive short-term price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100